| Abstract | Uvod: Cilj ove studije je istražiti značenje određivanja VEGF-a u serumu i bFGF-a u
urinu u različitim fazama rasta hemangioma kod djece.
Ispitanici i metode: Riječ je o prospektivnoj studiji istraživanja parova (case-control
study), koja je uključila pedeset bolesnika (N=50) s hemangiomima u fazi proliferacije
i pedeset bolesnika (N=50) s hemangiomima u fazi involucije i sto pacijenata-zdravih
kontrola (N=100) usporedive dobi i spola prema skupini bolesnika. Imunokemijskom
metodom (ELISA) određena je vrijednost VEGF-a u serumu i bFGF-a u urinu u fazi
proliferativnog rasta hemangioma i u fazi involucije hemangioma. Rezultati su se
usporedili s rezultatima analize kontrolne skupine djece usporedive dobi i spola, i
drugih kliničkih pokazatelja.
Rezultati: Usporedbom vrijednosti VEGF-a u serumu i bFGF-a u urinu između faza
proliferacije i involucije u skupini pacijenata s IH, nije bilo statistički značajnih razlika.
Kontrolna skupina, imala je značajno veće vrijednosti VEGF u mjereno u fazi
proliferacije IH (P=0,009). Isto tako, kontrolna skupina, imala je značajno veće
vrijednosti VEGF-a, mjereno i u fazi involucije IH (P=0,019). Mjereno u fazi proliferacije
IH, u kontrolnoj skupini značajno je više ispitanika imalo vrijednosti bFGF-a u urinu
≥0,31 (najniža vrijednost koja je bila detektabilna na uređaju): 24,0% naprema 4,0%;
P=0,008. Razina bFGF-a u urinu u fazi involucijskog rasta IH u usporedbi između
ispitivane i kontrolne skupine nije pokazala statističku značajnu razliku (P=0,617).
Zaključak: Iako se smatra kako IH nastaju kao rezultat disregulacije angiogeneze i
vaskulogeneze pod utjecajem angiogenih čimbenika, poglavito VEGF-a i bFGF-a, ovo
istraživanje nije pokazalo da se kod djece u proliferativnoj fazi rasta hemangioma
nalaze više vrijednosti VEGF-a u serumu i bFGF-a u urinu u odnosu na involutivnu
fazu. |
| Abstract (english) | Objective: The aim of this study is to investigate the importance of determining VEGF
in serum and bFGF in urine in various stages of growth of hemangiomas in children.
Patients and methods: This is a prospective study of research pairs (case-control
study), which includes fifty patients (N = 50) with hemangiomas in the stage of
proliferation and fifty patients (N = 50) with hemangiomas in the involution phase and
hundred healthy patients (N = 100) as a control group of comparable age and sex of
the patient group. Immunoassay (ELISA) is determined by the value of VEGF and
bFGF in serum and urine in the proliferative phase of hemangioma growth and
involution phase of the hemangioma. The results were compared with the results of a
control children group of comparable age and sex, and other clinical indicators.
Results: Comparison of VEGF serum and bFGF values in urine between phase of
proliferation and involution in the group of patients with IH did not show statistically
significant differences. The control group had significantly higher VEGF values
measured in the proliferation phase IH (P = 0.009). Likewise, the control group had
significantly higher values of VEGF, measured in the involution phase IH (P = 0.019).
Significantly more subjects in the control group had bFGF values in urine ≥ 0.31 (the
lowest value found on the device) measured in the proliferation phase IH (24.0%
versus 4.0%; P = 0.008). The level of bFGF in urine in the involution phase IH
compared to the examined and control group did not show statistically significant
difference (P = 0.617).
Conclusion: Although IH is thought to be a result of disregulation of angiogenesis and
vasculogenesis under the influence of angiogenic factors, notably VEGF and bFGF,
this research has not demostrated that VEGF serum values and bFGF in urine in the
proliferation phase of hemangioma are higher compared to the involution phase. |
